Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dannex Ayrton StarwinXGHA:DASPHARMA 3 5-Year ROIIC % is 0.00 as of . 20. GuruFocus rates XGHA:DASPHARMA with a GF Score™ of 3/100. The stock has 1 warning sign investors should review. Among 902 Drug Manufacturers companies, Dannex Ayrton Starwin ranks worse than 110864.63% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Dannex Ayrton Starwin does not have enough data to calculate 5-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Dannex Ayrton Starwin 5-Year ROIIC % Related Terms
Dannex Ayrton Starwin 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Dannex Ayrton Starwin's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dannex Ayrton Starwin 5-Year ROIIC % Chart
Dannex Ayrton Starwin Annual Data
Trend
5-Year ROIIC %
Dannex Ayrton Starwin Semi-Annual Data
5-Year ROIIC %
XGHA:DASPHARMA vs : 5-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dannex Ayrton Starwin's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dannex Ayrton Starwin 5-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dannex Ayrton Starwin's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Dannex Ayrton Starwin's 5-Year ROIIC % falls into.
Dannex Ayrton Starwin's 5-Year ROIIC % for the quarter that ended in is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( () - () )
/
( () - () )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a 5-Year ROIIC % of 0.00 as of . 20. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Dannex Ayrton Starwin and its competitors. According to the industry distribution chart, Dannex Ayrton Starwin ranks #999999 out of 902 companies in the Drug Manufacturers industry.
Is Dannex Ayrton Starwin's 5-Year ROIIC % too high?
Dannex Ayrton Starwin's current 5-Year ROIIC % is 0.00. Based on the distribution chart, Dannex Ayrton Starwin ranks #999999 out of 902 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dannex Ayrton Starwin has a GF Score™ of 3/100, reflecting its overall financial health beyond just this single metric.
How does Dannex Ayrton Starwin's 5-Year ROIIC % compare to ?
According to the Drug Manufacturers industry distribution chart, Dannex Ayrton Starwin ranks #999999 out of 902 companies for 5-Year ROIIC %. This places Dannex Ayrton Starwin in the lower half of its industry. The industry median 5-Year ROIIC % is 2.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Drug Manufacturers company?
The median 5-Year ROIIC % among Drug Manufacturers companies is 2.47, based on 902 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Dannex Ayrton Starwin and its competitors. For the Drug Manufacturers industry, the median 5-Year ROIIC % is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dannex Ayrton Starwin's current 5-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dannex Ayrton Starwin stock overvalued right now?
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a current 5-Year ROIIC % of 0.00. The current 5-Year ROIIC % is 0.00. Dannex Ayrton Starwin's overall GF Score™ is 3/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Dannex Ayrton Starwin (XGHA:DASPHARMA), the current 5-Year ROIIC % is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dannex Ayrton Starwin PLC is a pharmaceutical company. The company offers a product range that includes tablets, capsules, liquids syrups and suspensions, powders, ointments, and chemicals. It also manufactures and distributes Vitamin C.
3GF Score
Get the complete analysis for XGHA:DASPHARMA
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:DASPHARMA has been successfully added to your 
